4D MOLECULAR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.7 USD | +0.23% |
|
-2.58% | +26.85% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 8.42M | Sales 2025 * | 10.07M | Capitalization | 1.33B |
|---|---|---|---|---|---|
| Net income 2024 * | -158M | Net income 2025 * | -191M | EV / Sales 2024 * | 98.1 x |
| Net cash position 2024 * | 502M | Net cash position 2025 * | 403M | EV / Sales 2025 * | 91.9 x |
| P/E ratio 2024 * |
-8.48
x | P/E ratio 2025 * |
-7.44
x | Employees | 171 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on 4D Molecular Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.23% | ||
| 1 week | -2.58% | ||
| Current month | +7.40% | ||
| 1 month | -2.47% | ||
| 3 months | -7.72% | ||
| 6 months | +132.58% | ||
| Current year | +26.85% |
1 week
24.27
27.09
1 month
22.7528.43
Current year
16.6436.25
1 year
9.4436.25
3 years
5.3236.25
5 years
5.3255.11
10 years
5.3255.11
| Managers | Title | Age | Since |
|---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 13-09-11 |
David Kirn
FOU | Founder | 62 | 13-09-11 |
Uneek Mehra
DFI | Director of Finance/CFO | 51 | 23-09-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Milligan
CHM | Chairman | 63 | 20-07-31 |
Susannah Gray
BRD | Director/Board Member | 63 | 20-06-30 |
Charles Theuer
BRD | Director/Board Member | 60 | 15-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.74% | 0 M€ | -4.28% | ||
| 0.06% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 25.7 | +0.23% | 397,446 |
| 24-05-09 | 25.64 | -2.62% | 323,004 |
| 24-05-08 | 26.33 | -1.75% | 340,145 |
| 24-05-07 | 26.8 | +0.15% | 334,995 |
| 24-05-06 | 26.76 | +1.44% | 371,209 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
25.7
USD
Average target price
52.3
USD
Spread / Average Target
+103.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.85% | 1.33B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- FDMT Stock
